According to the European Organization for Research and Treatment of Cancer classification, primary cutaneous follicle center cell lymphoma is not associated with the t(14;18)(q32;q21) and only rarely expresses bcl-2 protein. To further investigate this issue, we evaluated a series of 20 patients (14 men, 6 women) with primary cutaneous follicular lymphoma (PCFL). The presenting skin lesion was located in the head and neck region in 16 of 20 patients. Most cases were grade 2 (6/20) or grade 3 (13/20), and all had a follicular architecture. Immunohistochemical analysis demonstrated bcl-2 expression in 8 cases (40%), and expression was inversely related to the grade. Of 7 grade 1 or 2 cases, 5 (71%) were positive, whereas only 3 (23%) of 13 grade 3 cases were positive for bcl-2. Clonal immunoglobulin heavy chain gene rearrangements were detected in 9 (45%) of 20 cases. In 4 (20%) of 20 cases, we identified the major breakpoint of the t(14;18) by polymerase chain reaction, 3 of which were grade 1 or 2. We conclude that bcl-2 protein expression and the t(14;18) are present in a subset of PCFL, particularly in lower grade cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1309/2TJU-DNLQ-5JBA-AB4T | DOI Listing |
Cureus
December 2024
Pathology, Sir Ganga Ram Hospital, New Delhi, IND.
Primary cutaneous anaplastic large cell lymphoma (ALCL) is a very uncommon type of CD30-positive T-cell lymphoma, and it very rarely affects the forehead. We report the case of a 68-year-old male presenting with an ulcerative lesion on the right forehead, initially suspected as a benign condition. Fine needle aspiration suggested a lymphoproliferative disorder, with biopsy and immunohistochemistry confirming primary cutaneous ALCL (CD30-positive, anaplastic lymphoma kinase [ALK]-negative).
View Article and Find Full Text PDFJID Innov
March 2025
Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In this study, data were analyzed from the phase 3 trial of lenabasum in DM.
View Article and Find Full Text PDFPostepy Dermatol Alergol
December 2024
Department of Dermatology and Venerology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Introduction: Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.
Aim: We present 3 cases of pemphigus patients who had undergone rituximab treatment.
Material And Methods: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions.
Plast Surg (Oakv)
February 2025
Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Lipohypertrophy is the most reported cutaneous complication of insulin injection. In cases refractory to conservative management, liposuction has been proposed as a treatment. This review aims to evaluate the use of liposuction for the treatment of insulin-induced lipohypertrophy.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
There is limited data on the risk of second primary malignancies (SPMs) in Asian melanoma survivors. This study aimed to identify the risk of SPMs in Asian melanoma survivors. Standardized incidence ratios (SIRs) were calculated for overall and specific SPMs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!